12 FDA Panel Questions on Paclitaxel-Coated Devices

After two days of presentations regarding the death risk that may be associated with paclitaxel-coated balloons and paclitaxel-eluting stents on the market and in clinical trials, FDA learned a lot about but the agency still has a lot of work to do before any concrete decisions are made regarding the risk-benefit of the devices in question.While an FDA advisory panel struggled with data discrepancies last week, panel members did attempt to answer these 12 questions for the agency.